Reverse-phase high-performance liquid chromatography is the default technique for assessing synthetic peptide purity, and it did not become the default by accident. Understanding why it fits peptides so well also shows you precisely where it stops being informative.
The separation principle
In reverse-phase chromatography the stationary phase is non-polar — typically silica with C18 or C8 alkyl chains bonded to it — and the mobile phase is polar, usually water and acetonitrile with an acidic modifier. Analytes partition between the two. More hydrophobic molecules interact more strongly with the alkyl chains, are retained longer, and elute later as the proportion of organic solvent rises through the gradient.
This suits peptides for a simple reason: hydrophobicity in a peptide is a sequence property, distributed across the residues. Two peptides differing by a single amino acid usually differ measurably in hydrophobicity, so the method can resolve compounds that are structurally very close. That is exactly the discrimination synthetic peptide analysis requires, because the impurities that matter are near-relatives of the target.
Why the acid is there
Trifluoroacetic acid at around 0.1% is the classic mobile-phase modifier. It does two jobs: it keeps the mobile phase at low pH so that acidic side chains stay protonated and the peptide’s charge state is uniform, and it ion-pairs with basic residues, masking their charge and improving peak shape.
The consequence follows a peptide out of the column. TFA remains associated with the purified material as a counter-ion, contributing real mass to the lyophilised powder without contributing any peptide. That is the chemistry behind the gap between chromatographic purity and net peptide content, and it is why counter-ion form belongs on a specification.
What the method resolves well
Deletion sequences missing one residue, truncated chains, incompletely deprotected material carrying a residual protecting group, and oxidised variants such as methionine sulfoxide all typically shift hydrophobicity enough to separate under a well-chosen gradient. Diastereomers arising from racemisation during synthesis often separate too, though less reliably.
Where it is blind
UV detection at 214 nm sees the amide backbone, so anything without an amide bond is invisible: inorganic salts, water, many scavengers, and the counter-ion itself. Those materials are on the balance and absent from the chromatogram, which is the whole reason a mass-based measurement is a separate exercise.
The method also cannot confirm identity. Two different compounds can co-elute; retention time is a property of the method rather than a fingerprint of the molecule. Identity confirmation is a mass spectrometry question, and a purity trace presented as proof of identity is being asked to do a job it cannot do.
Finally, anything that fails to elute is excluded from the calculation entirely. Strongly retained material that stays on the column simply does not appear, and a purity figure computed from what came off is silent about what did not.
Reading a method critically
Two parameters change a purity figure more than most buyers expect. Gradient slope: a shallow gradient over a long run separates near-eluting impurities; a steep one compresses them into the main peak and produces a higher number from identical material. Detection wavelength: 214 nm is the honest choice for a general peptide purity assessment, and a figure quoted only at 280 nm should prompt a question about the aromatic content of the sequence.
A supplier who discloses the method is inviting that scrutiny. That is the point. Each product in our catalogue is analysed by an independent laboratory using reverse-phase HPLC, with the result published on the product page so a purchaser can apply exactly this kind of reading before deciding to order.
Research use only. All products supplied by Battle Born Peptides are laboratory reference materials for in-vitro research and analytical use by qualified professionals. They are not drugs, foods, dietary supplements, cosmetics or medical devices; they are not approved by the FDA or any other regulator for use in humans or animals; and they are not intended to diagnose, treat, cure, mitigate or prevent any disease, or to affect the structure or any function of the body of humans or animals. Nothing in this article is preparation, handling or dosing guidance. See our full research-use terms.